Filtered By:
Condition: Diabetes Mellitus
Drug: Plavix

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 61 results found since Jan 2013.

STEMI vs NSTEACS management trends in non-invasive hospital
Conclusion NSTEACS patients in western province of KSA present at an older age are mostly males and have higher prevalence of hypertension and hyperlipidemia compared with STEMI patients. It is therefore important to identify patients with high-risk profile and put implement measures to reduce these factors.
Source: Indian Heart Journal - January 14, 2016 Category: Cardiology Source Type: research

Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures
Optimal antiplatelet inhibition is essential in patients undergoing neurointerventional procedures; however, variability in response to clopidogrel can contribute to thromboembolic and hemorrhagic complications. The present study evaluated the influence of diabetes mellitus and cigarette smoking on clopidogrel reactivity.
Source: Journal of Stroke and Cerebrovascular Diseases - October 19, 2015 Category: Neurology Authors: Ichiro Nakagawa, Hun Soo Park, Shohei Yokoyama, Takeshi Wada, Yasuo Hironaka, Yasushi Motoyama, Katsutoshi Takayama, Kimihiko Kichikawa, Hiroyuki Nakase Source Type: research

Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Abstract Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS). Our aim was to determine whether patients sustaining ACS while on chronic clopidogrel therapy have a worse prognosis than clopidogrel-naïve patients. A total of 5,386 consecutive ACS patients were prospectively characterised and followed-up for 30 days. Of them, 680 (13 %) were treated with clopidogrel prior to the index ACS. Major adverse cardiovascular events (MACE) were defined as death, recurrent ACS, stroke and/or sten...
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Asher E, Fefer P, Sabbag A, Herscovici R, Regev E, Mazin I, Shlomo N, Zahger D, Atar S, Hammerman H, Polak A, Beigel R, Matetzky S, PLATIS (Platelets and Thrombosis in Sheba) Study Group Tags: Thromb Haemost Source Type: research

Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up
Conclusions: Background diabetes mellitus, prior thrombolytic therapy, PAI-1 and vWF prestenting activity may be useful for MACE prediction over 28 months of follow-up.Cardiology 2015;132:176-181
Source: Cardiology - August 11, 2015 Category: Cardiology Source Type: research

Purpuric herpes zoster in patients in therapy with clopidogrel
Clopidogrel hydrogen sulfate is an adenosine diphosphate receptor antagonist belonging to the thienopyridine class. It is used for the prevention of vascular events in patients with atherothrombotic diseases manifested by recent myocardial infarction, ischemic stroke or peripheral arterial disease [1]. Clopidogrel provides greater reduction of the risk of recurrent ischemic events than acetylsalicylic acid (ASA) in patients with a medical history of coronary artery bypass surgery, diabetes mellitus and in those in therapy with statins [1].
Source: Journal of Clinical Virology - June 15, 2015 Category: Virology Authors: S. Veraldi, F. Vaira, G. Nazzaro Tags: Case report Source Type: research

Crossed Subcortical Aphasia (P1.048)
CONCLUSIONS: This patient is a rare case in which right-sided subcortical damage results in aphasia. The most comprehensive evidence on language lateralization comes from functional studies of healthy adults that differ in their degree of handedness. It appears that the degree of right-handedness correlates, with the degree of left hemisphere language dominance.Disclosure: Dr. Murray has nothing to disclose. Dr. Kase has nothing to disclose. Dr. Nguyen has nothing to disclose. Dr. Bickart has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Murray, C., Kase, C., Nguyen, T., Bickart, K. Tags: Cerebrovascular Disease and Interventional Neurology: The Spectrum of Small Vessel Cerebrovascular Disease Source Type: research

Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial Clinical Sciences
Conclusions— Unexpected interactions between assigned antiplatelet therapy and each of ischemic heart disease and normal/prehypertensive status accounted for increased mortality among patients with recent lacunar stroke given dual antiplatelet therapy. Despite extensive exploratory analyses, the mechanisms underlying these interactions are uncertain. Clinical Trial Registration— URL: http://www.SPS3ClinicalTrials.gov. Unique identifier: NCT00059306.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Sharma, M., Pearce, L. A., Benavente, O. R., Anderson, D. C., Connolly, S. J., Palacio, S., Coffey, C. S., Hart, R. G. Tags: Cerebral Lacunes, Antiplatelets Clinical Sciences Source Type: research

Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention A Contemporary Review
Chronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score ≥1. When these patients undergo percutaneous coronary intervention with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated. Before 2014, guidelines recommended the use of triple therapy (vitamin K antagonists, aspirin, and clopidog...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - September 15, 2014 Category: Cardiology Source Type: research

Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting
Conclusion Within a short period of 3–4 weeks, CR led to substantial improvements in key risk factors such as lipid profile, blood pressure, and physical fitness for all patients, even if CKD was present.
Source: European Journal of Preventive Cardiology - August 18, 2014 Category: Cardiology Authors: Voller, H., Gitt, A., Jannowitz, C., Karoff, M., Karmann, B., Pittrow, D., Reibis, R., Hildemann, S. Tags: Original scientific papers Source Type: research

Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research

Clopidogrel High-on-Treatment Platelet Reactivity in Acute Ischemic Stroke Patients
Conclusions: Clopidogrel-HTPR was found in 44% of the patients with acute ischemic stroke. Besides time-dependency of the clopidogrel effect, major risk factors for clopidogrel-HTPR were diabetes mellitus and higher HbA1c values. Further investigations are required to analyse if a function test guided strategy has the potential to optimize the antiplatelet therapy of acute stroke patients.
Source: Thrombosis Research - January 9, 2014 Category: Hematology Authors: Saskia H. Meves, Kay D. Schröder, Heinz G. Endres, Christos Krogias, Jan C. Krüger, Horst Neubauer Tags: Platelets and cell biology Source Type: research

Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)
ConclusionsLAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 17, 2013 Category: Cardiology Source Type: research

Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP VerifyNow and Inhibition of Platelet Reactivity Study)
In conclusion, 1/3 of patients with acute coronary syndromes who underwent percutaneous coronary intervention and stenting showed high on-treatment RPR on bedside monitoring. They had a worse prognosis, but the level of platelet inhibition was not independently associated with the incidence of ischemic or bleeding events.
Source: The American Journal of Cardiology - June 7, 2013 Category: Cardiology Authors: Francesco Saia, Massimiliano Marino, Gianluca Campo, Marco Valgimigli, Paolo Guastaroba, Nevio Taglieri, Stefano Tondi, Antonio Manari, Vincenzo Guiducci, Pietro Sangiorgio, Elisabetta Varani, Paolo Magnavacchi, Rossana De Palma, Antonio Marzocchi Tags: Coronary Artery Disease Source Type: research

Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)
Conclusions: LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578)
Source: Journal of the American College of Cardiology - April 12, 2013 Category: Cardiology Authors: Vivek Y. Reddy, Sven Möbius-Winkler, Marc A. Miller, Petr Neuzil, Gerhard Schuler, Jens Wiebe, Peter Sick, Horst Sievert Tags: Atrial Fibrillation Source Type: research